Latest Revenue Guidance News

EVZ Limited has issued earnings guidance for the first half of FY2025, forecasting revenue between $53 million and $55 million and EBITDA ranging from $2.4 million to $2.6 million based on preliminary figures.

DXN Limited reported a robust 58.1% revenue increase to $4.8 million in Q2 FY25, underpinned by strategic capital raising and new product innovation targeting AI infrastructure. The company is advancing key mining and telecom projects while streamlining operations to support its ambitious $16 million revenue guidance for FY25.

Aroa Biosurgery has reported its first quarter of positive operating cash flow since listing on the ASX in 2020, alongside robust revenue growth projections and new regulatory approvals across key international markets.

PlaySide Studios reports a 21% revenue decline in 1HFY25 and revises full-year guidance downward, citing slower Work for Hire contracts and underperforming original IP sales. Despite short-term challenges, the company remains bullish on upcoming game launches.

Burgundy Diamond Mines met most operational and revenue targets in 2024 but missed EBITDA guidance by 6%, while preparing the Point Lake open pit for ore production in early 2025.

Pureprofile Limited has upgraded its FY25 financial guidance following a robust first half, highlighted by a 22% revenue increase and a 30% surge in Q2, driven by strong international expansion and automation adoption.

SomnoMed reports a robust 19.8% revenue increase in Q2 FY25 and updates its full-year guidance, reflecting strong demand and operational improvements amid ongoing production enhancements.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.

Telix Pharmaceuticals has exceeded its full-year 2024 revenue guidance, driven by strong sales of its prostate cancer diagnostic Illuccix® and strategic pipeline advancements.